Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)

China · Delayed Price · Currency is CNY

15.99

+0.31 (1.98%)

At close: Oct 23, 2026

Market Cap	6.34B -6.7%
Revenue (ttm)	2.40B +36.7%
Net Income	281.10M +2,755.3%
EPS	0.71 +2,767.0%
Shares Out	396.81M
PE Ratio	22.55
Forward PE	n/a
Dividend	0.05 (0.31%)
Ex-Dividend Date	Jun 26, 2026

Volume	7,979,056
Open	15.50
Previous Close	15.68
Day's Range	14.86 - 16.12
52-Week Range	15.39 - 35.58
Beta	1.03
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About SHE:301246

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China, Asia, Europe, Africa, the Americas and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diacetylacyclovir; organic chemical raw materials comprising glyoxal, and o... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 2,258

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301246

Full Company Profile

Financial Performance

In 2025, SHE:301246's revenue was 1.94 billion, an increase of 9.53% compared to the previous year's 1.77 billion. Earnings were 119.05 million, an increase of 131.33%.

Financial Statements